Guillaume Vandenesch, CEO of Generare, stated, 'At Generare, we are unlocking nature's untapped potential, translating the complexity of microbial DNA into a scalable platform that can transform drug discovery. By leveraging cutting-edge biotechnology and data, we are accelerating the identification of new bioactive molecules, for medicine and beyond.'
Generare's approach utilizes shotgun cloning to break down thousands of genomes into millions of random fragments for parallel analysis, which is faster than traditional methods.
The company’s model creates a virtuous cycle of discovery—accumulating more data enhances their understanding of promising genetic clusters, resulting in better targeting for valuable molecules.
Founded in 2023 by Guillaume Vandenesch and Dr. Vincent Libis, Generare focuses on a data-driven discovery platform that arises from a decade of research into synthetic biology and computational biology.
Collection
[
|
...
]